Julia Enge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julia Enge has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Holger Amthauer
Department of Nuclear Medicine, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
1 shared publication - Jens Ricke
Department of Radiology, University Hospital, LMU Munich, Munich, Germany
1 shared publication - Konrad Mohnike
Diagnostisch Therapeutisches Zentrum
1 shared publication - Maciej Pech
Research Campus STIMULATE, University of Magdeburg, Otto-Hahn-Straße 2, 39106, Magdeburg, Saxony-Anhalt, Germany
1 shared publication - Max Seidensticker
Department of Radiology, University Hospital, LMU Munich, 81377 Munich, Germany
1 shared publication - Peter Hass
Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany
1 shared publication
Latest Publications
- Open Access
- 10 September 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 882
Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival
Background: Local ablative techniques are emerging in patients with oligometastatic disease from colorectal carcinoma, commonly described as less invasive than surgical methods. This single arm cohort seeks to determine whether such methods are suitable in patients with comorbidities or higher age. Methods: Two hundred sixty-six patients received radiofrequency ablation (RFA), CT-guided high-dose rate brachytherapy (HDR-BT) or Y90-radioembolization (Y90-RE) during treatment of metastatic colorectal cancer (mCRC). This cohort comprised of patients with heterogenous disease stages from single liver lesions to multiple organ systems involvement commonly following multiple chemotherapy lines. Data was reviewed retrospectively for patient demographics, previous therapies, initial or disease stages at first intervention, comorbidities and mortality. Comorbidity was measured using the Charlson Comorbidity Index (CCI) and age-adjusted Charlson Index (CACI) excluding mCRC as the index disease. Kaplan-Meier survival analysis and Cox regression were used for statistical analysis. Results: Overall median survival of 266 patients was 14 months. Age >= 70 years did not influence survival after local therapies. Similarly, CCI or CACI did not affect the patients prognoses in multivariate analyses. Moderate or severe renal insufficiency (n = 12; p = 0.005) was the only single comorbidity identified to negatively affect the outcome after local therapy. Conclusion: Interventional procedures for mCRC may be performed safely even in elderly and comorbid patients. In severe renal insufficiency, the use of invasive techniques should be limited to selected cases.
- 10 September 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 882
Open AccessLocal ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival
Background: Local ablative techniques are emerging in patients with oligometastatic disease from colorectal carcinoma, commonly described as less invasive than surgical methods. This single arm cohort seeks to determine whether such methods are suitable in patients with comorbidities or higher age. Methods: Two hundred sixty-six patients received radiofrequency ablation (RFA), CT-guided high-dose rate brachytherapy (HDR-BT) or Y90-radioembolization (Y90-RE) during treatment of metastatic colorectal cancer (mCRC). This cohort comprised of patients with heterogenous disease stages from single liver lesions to multiple organ systems involvement commonly following multiple chemotherapy lines. Data was reviewed retrospectively for patient demographics, previous therapies, initial or disease stages at first intervention, comorbidities and mortality. Comorbidity was measured using the Charlson Comorbidity Index (CCI) and age-adjusted Charlson Index (CACI) excluding mCRC as the index disease. Kaplan-Meier survival analysis and Cox regression were used for statistical analysis. Results: Overall median survival of 266 patients was 14 months. Age >= 70 years did not influence survival after local therapies. Similarly, CCI or CACI did not affect the patients prognoses in multivariate analyses. Moderate or severe renal insufficiency (n = 12; p = 0.005) was the only single comorbidity identified to negatively affect the outcome after local therapy. Conclusion: Interventional procedures for mCRC may be performed safely even in elderly and comorbid patients. In severe renal insufficiency, the use of invasive techniques should be limited to selected cases.